Compare RLMD & BKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | BKT |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.8M | 337.5M |
| IPO Year | 2012 | 1994 |
| Metric | RLMD | BKT |
|---|---|---|
| Price | $3.06 | $9.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 100.0K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $3.07 | $9.42 |
| 52 Week High | $8.00 | $11.23 |
| Indicator | RLMD | BKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 40.27 |
| Support Level | N/A | $9.50 |
| Resistance Level | $3.55 | $9.69 |
| Average True Range (ATR) | 0.43 | 0.13 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 4.05 | 15.30 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Blackrock Income Trust Inc is a closed-end management investment company. Its investment objective is to manage a portfolio of high-quality securities to achieve both preservation of capital and high monthly income. The fund seeks to achieve its investment objective by investing at least 65% of its assets in mortgage-backed securities.